IMNM has 36-month beta value of 1.79. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for IMNM is 48.31M, and currently, short sellers hold a 6.71% ratio of that float. The average trading volume of IMNM on April 18, 2024 was 738.34K shares.
IMNM) stock’s latest price update
Immunome Inc (NASDAQ: IMNM)’s stock price has plunge by -5.54relation to previous closing price of 18.40. Nevertheless, the company has seen a -14.51% plunge in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-04-04 that IMNM, SLOIF and TMQ have been added to the Zacks Rank #5 (Strong Sell) List on April 4, 2023.
IMNM’s Market Performance
Immunome Inc (IMNM) has experienced a -14.51% fall in stock performance for the past week, with a -21.36% drop in the past month, and a 24.14% rise in the past quarter. The volatility ratio for the week is 7.03%, and the volatility levels for the past 30 days are at 7.12% for IMNM. The simple moving average for the last 20 days is -21.30% for IMNM stock, with a simple moving average of 40.29% for the last 200 days.
Analysts’ Opinion of IMNM
Many brokerage firms have already submitted their reports for IMNM stocks, with Guggenheim repeating the rating for IMNM by listing it as a “Buy.” The predicted price for IMNM in the upcoming period, according to Guggenheim is $35 based on the research report published on April 15, 2024 of the current year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see IMNM reach a price target of $30. The rating they have provided for IMNM stocks is “Outperform” according to the report published on January 29th, 2024.
Wedbush gave a rating of “Outperform” to IMNM, setting the target price at $12 in the report published on December 19th of the previous year.
IMNM Trading at -24.75% from the 50-Day Moving Average
After a stumble in the market that brought IMNM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.86% of loss for the given period.
Volatility was left at 7.12%, however, over the last 30 days, the volatility rate increased by 7.03%, as shares sank -27.82% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.96% upper at present.
During the last 5 trading sessions, IMNM fell by -14.51%, which changed the moving average for the period of 200-days by +119.72% in comparison to the 20-day moving average, which settled at $21.75. In addition, Immunome Inc saw 62.43% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IMNM starting from SIEGALL CLAY B, who purchase 169,204 shares at the price of $5.91 back on Oct 02 ’23. After this action, SIEGALL CLAY B now owns 319,636 shares of Immunome Inc, valued at $999,996 using the latest closing price.
Turner Bruce, the Chief Strategy Officer of Immunome Inc, purchase 42,300 shares at $5.91 during a trade that took place back on Oct 02 ’23, which means that Turner Bruce is holding 42,300 shares at $249,993 based on the most recent closing price.
Stock Fundamentals for IMNM
Current profitability levels for the company are sitting at:
- -2.22 for the present operating margin
- 0.93 for the gross margin
The net margin for Immunome Inc stands at -2.2. The total capital return value is set at -0.32. Equity return is now at value -156.45, with -123.77 for asset returns.
Based on Immunome Inc (IMNM), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at 8.65. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is 115.05.
Currently, EBITDA for the company is -36.27 million with net debt to EBITDA at 4.06. When we switch over and look at the enterprise to sales, we see a ratio of 64.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.63.
Conclusion
To put it simply, Immunome Inc (IMNM) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
